Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions

Authors

Derek J Leishman ¹, Jessica Brimecombe ², William Crumb ³, Simon Hebeisen ⁴, Steve Jenkinson ⁵, Peter J Kilfoil ⁶, Hiroshi Matsukawa ⁷, Karim Melliti ⁸, Yusheng Qu ⁹

Affiliations

• ¹Eli Lilly and Company, Indianapolis, Indiana, USA.
• ²Charles River Laboratories, Cleveland, Ohio, USA.
• ³Nova Research Laboratories, New Orleans, Louisiana, USA.
• ⁴B'SYS GmbH, Basel, Switzerland.
• ⁵Metrion Biosciences Ltd., Cambridge, UK.
• ⁶Pfizer Global Research & Development, Groton, Connecticut, USA.
• ⁷Mediford Corporation, Kamisu-shi, Ibaraki, Japan.
• ⁸Labcorp Early Development Laboratories Inc., Harrogate, UK.
• ⁹Amgen Research, Thousand Oaks, California, USA.

Journal

Journal of Pharmacological and Toxicological Methods

Volume 128, 2024, 107524, ISSN 1056-8719

DOI

10.1007/978-3-031-52197-3

PubMed

Read on PubMed.